Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma
ChiCTR2000037942Phase 4Recruiting
- Sponsor
- Changzhi People's Hospital
- Start
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Changzhi People's Hospital. Primary endpoint: Progression-free survival. Started Jun 2020; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2000037942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037942.